Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig
- 1 January 1989
- journal article
- Published by Springer Nature in Urological Research
- Vol. 17 (1) , 47-55
- https://doi.org/10.1007/bf00261051
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Histopathology of BCG and thiotepa treated bladdersUrological Research, 1986
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986
- Histological Parameters and Pitfalls in the Interpretation of Bladder Biopsies in Bacillus Calmette-Guerin Treatment of Superficial Bladder CancerJournal of Urology, 1986
- Experimental screening of BCG preparations produced for cancer immunotherapy: Safety and immunostimulating and antitumor activity of four consecutively produced batchesCancer Immunology, Immunotherapy, 1984
- Immunotherapy of Superficial Bladder CancerJournal of Urology, 1982
- Bacillus Calmette-guerin Immunotherapy of Superficial Bladder CancerJournal of Urology, 1980
- Antitumor Immunity. V. BCG-Induced Growth Inhibition of Murine Tumors. Effect of Hydrocortisone, Antiserum Against Theta Antigen, and Gamma-Irradiated BCGJNCI Journal of the National Cancer Institute, 1977
- GRANULOMATOUS INFLAMMATORY RESPONSE - REVIEW1976
- Tumor Regression Mediated by Mycobacterium bovis (Strain BCG). Effects of Isonicotinic Acid Hydrazide, Cortisone Acetate, and Antithymocyte SerumJNCI Journal of the National Cancer Institute, 1973